Peptide vaccines for cancer

Cancer Investigation
J Weber

Abstract

The revelation that immune cytolytic and helper T-cells recognize intracellularly degraded peptides processed via the proteosome apparatus, inserted into the endoplasmic reticulum and transported to the surface for association with major histocompatibility locus (MHC) molecules on specialized antigen-presenting cells has revolutionized the cancer vaccine field. Understanding the science of antigen processing and presentation has provided new reagents, delivery systems, and new investigative leads for the generation of immune responses against cancer. The cloning of tumor antigen genes has proceeded rapidly in melanoma, due to the ease with which melanoma-specific T-cells can be propagated in vitro, but breast, cervix, and lung cancer are not far behind. The cloning and identification of tumor antigens recognized by T-cells and data from initial clinical trials with peptides vaccines derived from those antigens are presented.

References

Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R ParkinsonJ H Doroshow
Dec 20, 1989·Journal of the National Cancer Institute·W H ClarkA C Halpern
Jan 1, 1988·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Y S FuG Orth
Aug 1, 1987·Archives of Dermatology·J C BystrynA Kopf
Nov 1, 1983·Journal of the American Academy of Dermatology·J J NordlundA B Lerner
Jan 1, 1983·Archives of Surgery·R R Paladugu, R H Yonemoto
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·P G CoulieT Boon
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·B MukherjiJ Meehan
Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Mar 1, 1994·The Journal of Experimental Medicine·A B BakkerC G Figdor
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Mar 1, 1996·The Journal of Experimental Medicine·R F WangS A Rosenberg
Mar 1, 1996·The Journal of Experimental Medicine·P F RobbinsS A Rosenberg
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y T ChenL J Old
Jul 3, 1996·International Journal of Cancer. Journal International Du Cancer·E JägerA Knuth
May 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·F M MarincolaS A Rosenberg
Dec 11, 1995·International Journal of Cancer. Journal International Du Cancer·M MarchandY Humblet
Jul 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·F M MarincolaS A Rosenberg
Dec 1, 1996·The Journal of Experimental Medicine·R F WangS A Rosenberg
Jan 1, 1997·Cancer Immunology, Immunotherapy : CII·K R JeromeO J Finn
Mar 1, 1997·Immunology Today·J Taylor-Papadimitriou, O J Finn
Dec 31, 1997·Journal of Immunotherapy·T KageshitaT Ono

❮ Previous
Next ❯

Citations

Sep 19, 2006·Advanced Drug Delivery Reviews·Sjoerd H van der BurgCornelis J M Melief
Apr 1, 2004·International Journal of Cancer. Journal International Du Cancer·Paola Sinibaldi VallebonaEnrico Garaci
Apr 18, 2008·Nature Reviews. Cancer·Cornelis J M Melief, Sjoerd H van der Burg
Sep 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eugene Y Chiang, Iwona Stroynowski
Apr 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eugene Y Chiang, Iwona Stroynowski
Apr 19, 2007·Cancer Research·Rolf K SwobodaDorothee Herlyn
Mar 18, 2004·Cancer Research·Yurika SugitaMorito Monden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.